Unilabs to Market Diagnoplex's Colon Cancer Screening Test | GenomeWeb

NEW YORK (GenomeWeb News) – Diagnoplex and Unilabs said today that they have signed an agreement to commercialize Colox, Diagnoplex's minimally invasive colorectal cancer assay, within the Unilabs network.

The test will be available initially in the Swiss and Swedish markets, the companies said.

Colox, Diagnoplex's lead product, is a PCR-based test intended for the systematic screening of colorectal cancer. The gene signature underlying Colox has been designed to detect early and advanced disease stages with "outstanding results and reliability," said Diagnoplex.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: tool to discover copy number variants, single-nucleus RNA sequencing study of myoblasts, and more.

A study of Tasmanian devil genomes suggests they are evolving resistance to devil facial tumor disease.

Theranos has withdrawn its request for emergency clearance of a Zika virus blood test, according to the Wall Street Journal.

An assistant professor who was fired from Mount Sinai School of Medicine has allegedly shot the school's dean, the New York Times reports.